前列腺切除术后患者常规影像与18F-氟环丁氨酸PET/CT引导挽救性放疗的无失败生存差异:EMPIRE-1试验的事后分层分析
EMPIRE-1试验事后分层分析比较前列腺切除术后复发患者接受常规影像(A组)与常规影像联合18F-氟环丁氨酸PET/CT(B组)引导挽救性放疗的无失败生存(FFS)。按随机分层标准亚组分析显示,PSA<2 ng/mL患者B组36和48个月FFS均显著高于A组,PSA≥2 ng/mL患者两组无显著差异;不良病理或ADT意向各亚组中B组FFS优势多数维持。
要点
- PSA<2 ng/mL患者B组36个月FFS 83.2% vs A组66.5%,48个月83.2% vs 56.2%,均P<0.001。
- PSA≥2 ng/mL患者两组FFS无显著差异。
- 不良病理患者B组48个月FFS 68.9% vs A组42.8%,P<0.001,36个月未达显著。
核心结论
- 在挽救性放疗计划中加入18F-氟环丁氨酸PET/CT带来的生存优势在有无不良病理或ADT意向的患者中均维持。
- PSA<2 ng/mL患者从加入18F-氟环丁氨酸PET/CT的挽救性放疗中获得生存获益,PSA≥2 ng/mL患者未显示获益。
研究设计与样本
- EMPIRE-1试验的事后分层分析,将患者按方案预设随机分层标准(PSA<2.0 vs ≥2.0 ng/mL、不良病理、ADT意向)细分后比较组间FFS。
- EMPIRE-1将患者随机分配至常规影像(骨扫描+腹盆腔CT或MRI)引导SRT计划(A组)或常规影像联合18F-氟环丁氨酸PET/CT引导SRT计划(B组)。
- A组81例、B组76例接受按方案SRT。
主要发现
- 中位随访3.5年(95%CI 3.0-4.0)。
- A组36和48个月FFS分别为63.0%和51.2%,B组36和48个月FFS均为75.5%。
- PSA<2 ng/mL(均值0.42±0.42 ng/mL)患者B组较A组36个月FFS 83.2%(95%CI 70.0-91.0)vs 66.5%(95%CI 51.6-77.8),P<0.001;48个月83.2%(95%CI 70.0-91.0)vs 56.2%(95%CI 40.5-69.2),P<0.001。
- PSA≥2 ng/mL患者两组FFS无显著差异。
- 不良病理患者B组较A组48个月FFS 68.9%(95%CI 52.1-80.8)vs 42.8%(95%CI 26.2-58.3),P<0.001,36个月随访时未达显著。
临床怎么用
- 作者结论认为,无论是否存在不良病理或ADT意向,在SRT计划中加入18F-氟环丁氨酸PET/CT的生存优势均维持。
- 作者结论认为,PSA<2 ng/mL患者可从加入18F-氟环丁氨酸PET/CT的SRT中获得生存获益,PSA≥2 ng/mL患者未显示获益。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The EMPIRE-1 (Emory Molecular Prostate Imaging for Radiotherapy Enhancement 1) trial reported a survival advantage in recurrent prostate cancer salvage radiotherapy (SRT) guided by 18F-fluciclovine PET/CT versus conventional imaging. We performed a post hoc analysis of the EMPIRE-1 cohort stratified by protocol-specified criteria, comparing failure-free survival (FFS) between study arms. Methods: EMPIRE-1 randomized patients to SRT planning via either conventional imaging only (bone scanning plus abdominopelvic CT or MRI) (arm A) or conventional imaging plus 18F-fluciclovine PET/CT (arm B). Randomization was stratified by prostate-specific antigen (PSA) level (<2.0 vs. ≥ 2.0 ng/mL), adverse pathology, and androgen-deprivation therapy (ADT) intent. We subdivided patients in each arm using the randomization stratification criteria and compared FFS between patient subgroups across study arms. Results: Eighty-one and 76 patients received per-protocol SRT in study arms A and B, respectively. The median follow-up was 3.5 y (95% CI, 3.0-4.0). FFS was 63.0% and 51.2% at 36 and 48 mo, respectively, in arm A and 75.5% at both 36 and 48 mo in arm B. Among patients with a PSA of less than 2 ng/mL (mean, 0.42 ± 0.42 ng/mL), significantly higher FFS was seen in arm B than arm A at 36 mo (83.2% [95% CI, 70.0-91.0] vs. 66.5% [95% CI, 51.6-77.8], P < 0.001) and 48 mo (83.2% [95% CI, 70.0-91.0] vs. 56.2% [95% CI, 40.5-69.2], P < 0.001). No significant difference in FFS between study arms in patients with a PSA of at least 2 ng/mL was observed. Among patients with adverse pathology, significantly higher FFS was seen in arm B than arm A at 48 mo (68.9% [95% CI, 52.1-80.8] vs. 42.8% [95% CI, 26.2-58.3], P < 0.001) though not at the 36-mo follow-up. FFS was higher in patients without adverse pathology in arm B versus arm A (90.2% [95% CI, 65.9-97.5] vs. 73.1% [95% CI, 42.9-89.0], P = 0.006) at both 36 and 48 mo. Patients in whom ADT was intended in arm B had higher FFS than those in arm A, with the difference reaching statistical significance at 48 mo (65.2% [95% CI, 40.3-81.7] vs. 29.1 [95% CI, 6.5-57.2], P < 0.001). Patients without ADT intent in arm B had significantly higher FFS than patients in arm A at 36 mo (80.7% [95% CI, 64.9-90.0] vs. 68.0% [95% CI, 51.1-80.2]) and 48 mo (80.7% [95% CI, 64.9-90.0] vs. 58.6% [95% CI, 41.0-72.6]). Conclusion: The survival advantage due to the addition of 18F-fluciclovine PET/CT to SRT planning is maintained regardless of the presence of adverse pathology or ADT intent. Including 18F-fluciclovine PET/CT to SRT leads to survival benefits in patients with a PSA of less than 2 ng/mL but not in patients with a PSA of 2 ng/mL or higher.
引用
- Lawal IO, Jani AB, Adediran OA, et al. Differences in Failure-Free Survival After Salvage Radiotherapy Guided by Conventional Imaging Versus 18F-Fluciclovine PET/CT in Postprostatectomy Patients: A Post Hoc Substratification Analysis of the EMPIRE-1 Trial. J Nucl Med. 2022. PMID: 36328489. doi:10.2967/jnumed.122.264832
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。